1.74
-0.035(-1.98%)
Currency In USD
| Previous Close | 1.77 |
| Open | 1.74 |
| Day High | 1.74 |
| Day Low | 1.74 |
| 52-Week High | 3.44 |
| 52-Week Low | 0.98 |
| Volume | 3,017 |
| Average Volume | 34,179 |
| Market Cap | 69.98M |
| PE | -8.68 |
| EPS | -0.2 |
| Moving Average 50 Days | 1.81 |
| Moving Average 200 Days | 1.83 |
| Change | -0.04 |
If you invested $1000 in BeyondSpring Inc. (BYSI) since IPO date, it would be worth $103.27 as of October 20, 2025 at a share price of $1.735. Whereas If you bought $1000 worth of BeyondSpring Inc. (BYSI) shares 5 years ago, it would be worth $124.55 as of October 20, 2025 at a share price of $1.735.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a p